This page tracks major developments affecting Mounjaro patients in 2026. We update this page as significant news breaks: FDA actions, supply changes, major studies, insurance coverage shifts, and pricing updates. Items appear in reverse chronological order, with the most recent at the top.
Mounjaro Supply Stable Across All Doses in Q2 2026
Eli Lilly's expanded production capacity has stabilized Mounjaro supply at all six dose strengths through Q2 2026. The FDA removed all tirzepatide doses from the official drug shortage list in late 2024, and recent pharmacy reports confirm consistent availability at major chain and independent pharmacies. Patients who experienced shortages in 2023-2024 should now find prescriptions easier to fill. Eli Lilly has also expanded automated production lines at its Indiana and North Carolina facilities to support continued demand growth.
New Insurance Plans Begin Covering Tirzepatide for Sleep Apnea
Following the late-2024 FDA approval of Zepbound for moderate-to-severe obstructive sleep apnea, several major insurance carriers have updated their formularies to cover tirzepatide for the OSA indication. Coverage typically requires documented diagnosis through sleep study and BMI of 30 or higher. Sleep medicine specialists report increased patient interest and a growing comfort with prescribing the medication for OSA-specific cases. Coverage details vary by plan; check directly with your insurer.
FDA Continues Restrictions on Compounded Tirzepatide
The FDA has maintained restrictions on widespread compounding of tirzepatide following the drug's removal from the shortage list in late 2024. State-licensed compounding pharmacies operating under section 503A continue to provide patient-specific compounded tirzepatide in limited circumstances, but mass production by 503B facilities is no longer permitted. Patients seeking compounded versions should verify their pharmacy's state licensing and ask about their specific authorization to compound tirzepatide.
Long-Term Cardiovascular Outcomes Trial Continues for Tirzepatide
The SURPASS-CVOT trial, examining the cardiovascular safety and benefit of tirzepatide in patients with type 2 diabetes and established cardiovascular disease, continues to enroll and follow patients. Initial results are expected in 2027. The trial is one of the most-watched cardiovascular outcomes studies in metabolic medicine, as it will determine whether tirzepatide produces cardiovascular benefits comparable to or exceeding those documented for semaglutide in the SUSTAIN-6 and SELECT trials.
Mounjaro Savings Card Program Renewed for 2026
Eli Lilly has renewed the Mounjaro Savings Card program for 2026 with terms substantially similar to 2025. Eligible commercially insured patients can continue to access Mounjaro for as little as $25 per month, with maximum savings of $150 per fill. The program covers up to 13 fills over 12 consecutive months, with annual re-enrollment available. Government-insured patients (Medicare, Medicaid) remain ineligible per federal regulations.